In our initial analysis of a cohort of 70 patients with NSCLC who received anti-PD-L1 (atezolizumab) monotherapy as a second or third line (cohort 1; Supplementary Table 4), PR was rarely observed in patients with preDP-Temrahi (>17.2%, Q2 and Q3), whereas it was clearly evident in patients with preDP-Temralo (<17.2%, Q1 and Q4) (Fig. 6c, d). This evidence concerns the gene CD274 and non-small cell lung carcinoma.